Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VSTA- Support could be heading up to 3.50 and above.
VSTA- Alot of shares out there in the $3.50 range.
RECENT INSIDER TRADING ACTIVITY: VISTAGEN THERAPEUTICS INCDate Name Transaction Num Shares Price(s) Value
05/11/11 RICE A FRANKLIN Grant 229,521 $3.50 803,323.50
05/11/11 SAXE JON S Grant 17,354 $3.50 60,739.00
05/11/11 SINGH SHAWN K Grant 76,087 $3.50 266,304.50
05/11/11 SNODGRASS H RALPH Grant 545,416 $3.50 1.91 Mil
05/09/11 JONES STEPHANIE Sold 4.98 Mil NA NA
VSTA Research material for VistaGen Therapeutics, Inc. (VSTA)
VSTA New website: http://www.VistaGen.com
VSTA Fact Sheet and Information: http://www.vistagen.com/Investors_Overview/default.aspx
VistaGen Therapeutics IR Kit http://www.missionir.com/clientsummary/vsta.pdf
VSTA Research material for VistaGen Therapeutics, Inc. (VSTA)
VSTA New website: http://www.VistaGen.com
VSTA Fact Sheet and Information: http://www.vistagen.com/Investors_Overview/default.aspx
VistaGen Therapeutics IR Kit http://www.missionir.com/clientsummary/vsta.pdf
VSTA- This sure shows that they have alot of things going on.
VSTA-In parallel with its drug rescue activities, VistaGen is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube(TM) platform.
VSTA- Cheat sheet
Vistagen Therapeutic (VSTA)
3.1000 unch (unch) Thursday, Nov 10th, 2011 9:37A EST
Trader's Cheat Sheet
Support/Resistance Levels Price Key Turning Points
Current Price 3.1000 Current Price
2.8899 38.2% Retracement from 4 Week High
2.8250 50% Retracement from 4 Week High/Low
2.7601 38.2% Retracement from 4 Week Low
2.5843 38.2% Retracement from 13 Week High
38.2% Retracement from 52 Week High
4 Week Low 2.5500
2.4250 50% Retracement from 13 Week High/Low
50% Retracement from 52 Week High/Low
2.2657 38.2% Retracement from 13 Week Low
38.2% Retracement from 52 Week Low
13 Week Low
52 Week Low 1.7500
VSTA- And I hear that 95% of this float is held by insiders, making it even smaller.
VSTA- This is what could set VSTA ahead of the few others in this business.
VSTA- Cheat sheet
Vistagen Therapeutic (VSTA)
3.1000 unch (unch) Thursday, Nov 10th, 2011 9:37A EST
Trader's Cheat Sheet
Support/Resistance Levels Price Key Turning Points
Current Price 3.1000 Current Price
2.8899 38.2% Retracement from 4 Week High
2.8250 50% Retracement from 4 Week High/Low
2.7601 38.2% Retracement from 4 Week Low
2.5843 38.2% Retracement from 13 Week High
38.2% Retracement from 52 Week High
4 Week Low 2.5500
2.4250 50% Retracement from 13 Week High/Low
50% Retracement from 52 Week High/Low
2.2657 38.2% Retracement from 13 Week Low
38.2% Retracement from 52 Week Low
13 Week Low
52 Week Low 1.7500
VSTA- L2 is real thin, small float
Vistagen Therapeutic (VSTA)
3.1000 unch (unch)
Stock Price Quote as of Thursday, Nov 10th, 2011 9:37A EST (OTC-BB)
High 3.1000 Low 3.1000
52Wk High 3.1000 52Wk Low 1.7500
Open 3.1000 Prev Close 3.1000
Volume 500 Avg Volume 815
VSTA- Needs volume
Vistagen Therapeutic (VSTA)
3.1000 unch (unch)
Stock Price Quote as of Thursday, Nov 10th, 2011 9:37A EST (OTC-BB)
High 3.1000 Low 3.1000
52Wk High 3.1000 52Wk Low 1.7500
Open 3.1000 Prev Close 3.1000
Volume 500 Avg Volume 815
VSTA- Tight
Support & ResistanceGet Cheat Sheet
2nd Resistance Point 3.1000
1st Resistance Point 3.1000
Last Price 3.1000
1st Support Level 3.1000
2nd Support Level 3.1000
VSTA Support & ResistanceGet Cheat Sheet
2nd Resistance Point 3.1000
1st Resistance Point 3.1000
Last Price 3.1000
1st Support Level 3.1000
2nd Support Level 3.1000
VSTA- The opposite of dilution
VSTA recently announced that they reduced the number of shares of common stock the Company is authorized to issue from 400,000,000 shares to 200,000,000 shares
VSTA- Could effect share price in a huge way in the positive direction.
VSTA recently announced that they reduced the number of shares of common stock the Company is authorized to issue from 400,000,000 shares to 200,000,000 shares
VSTA-Read the bold print, it is what sets Vistagen from the rest.
VistaGen Therapeutics has the ability to work directly with human cells offers a way for pharmaceutical companies to save money while risking less of it. VistaGen has developed a way to use advanced stem cell technology to generate human cell based bioassay systems that allow new drug candidates to be effectively tested for possible toxicity without having to expend the volumes of money and effort required to take a drug all the way to human clinical trial. It’s a highly accurate and economical way to identify problems early on, in addition to making it feasible to cost-effectively develop non-toxic drug variants, so that promising drugs aren’t shelved unnecessarily.
VSTA- VistaGen Therapeutics has the ability to work directly with human cells offers a way for pharmaceutical companies to save money while risking less of it. VistaGen has developed a way to use advanced stem cell technology to generate human cell based bioassay systems that allow new drug candidates to be effectively tested for possible toxicity without having to expend the volumes of money and effort required to take a drug all the way to human clinical trial. It’s a highly accurate and economical way to identify problems early on, in addition to making it feasible to cost-effectively develop non-toxic drug variants, so that promising drugs aren’t shelved unnecessarily.
VSTA- And they are usually things that you brag about. Very attractive now but news will bring attention here. I think that is what investors are waiting for. You see there is no selling going on so the shares are being held real tight.
VSTA- With the instant equity they have aquired plus the $41 mil invested, I would not doubt they have a $100 mil interest. You know that will be coming back when they are finished.
VSTA-Management:
Shawn Singh, J.D.
Chief Executive Officer, Director
Mr. Singh has over 20 years of experience working with public and private biotechnology and pharmaceutical companies,
serving in numerous senior management roles. He served as Managing Principal of Cato BioVentures, a biopharmaceutical
venture capital firm, as Chief Business Officer of Cato Research Ltd., a global contract research and development
organization (CRO), as President of Echo Therapeutics (Nasdaq: ECTE), a medical device company targeting diabetes
management, and as Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN), a revenue-producing specialty
pharmaceutical company focused on cancer and infectious disease. Mr. Singh began his career as a corporate finance
attorney in the Silicon Valley offices of Morrison & Foerster LLP. Mr. Singh is a member of the State Bar of California.
Ralph Snodgrass, Ph.D.
President, Chief Scientific Officer, Director
Dr. Snodgrass founded VistaGen in 1998. He has over 18 years of experience in senior biotechnology management,
including as Chief Scientific Officer of Progenitor, Inc. He has more than 10 years of research experience as a professor
at the Lineberger Comprehensive Cancer Center, University North Carolina Chapel Hill School of Medicine, and as
a member of the Institute for Immunology, Basel, Switzerland. Dr. Snodgrass is a past Board Member of the Emerging
Company Section of the Biotechnology Industry Organization (BIO), and is a published and recognized pioneering expert
in stem cell biology with more than 20 years' experience in the uses of stem cells as biological tools for drug discovery
and development.
Gordon Keller, Ph.D.
Chairman, Scientific Advisory Board
Dr. Keller, recently named a "Top 25 Transformational Canadian" for his stem cell research, was appointed Director of
the McEwen Centre for Regenerative Medicine of the University Health Network in Toronto in 2007. He has published
more than 100 papers and is named on five patents. Dr. Keller is a former president of the International Society for Stem
Cell Research (ISSCR), the primary international organization of stem cell researchers, representing 3,800 scientists,
ethicists and clinicians worldwide. He is the Canada Research Chair in Embryonic Stem Cell Biology, a Professor at the
University of Toronto and a Senior Scientist in the Division of Stem Cell and Developmental Biology at the Ontario Cancer
Institute. Dr. Keller was a Professor in the Department of Gene and Cell Medicine at the Mt. Sinai School of Medicine in
New York where he was described by New York Magazine as one of "six doctors New York can't lose."
VSTA Management:
Shawn Singh, J.D.
Chief Executive Officer, Director
Mr. Singh has over 20 years of experience working with public and private biotechnology and pharmaceutical companies,
serving in numerous senior management roles. He served as Managing Principal of Cato BioVentures, a biopharmaceutical
venture capital firm, as Chief Business Officer of Cato Research Ltd., a global contract research and development
organization (CRO), as President of Echo Therapeutics (Nasdaq: ECTE), a medical device company targeting diabetes
management, and as Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN), a revenue-producing specialty
pharmaceutical company focused on cancer and infectious disease. Mr. Singh began his career as a corporate finance
attorney in the Silicon Valley offices of Morrison & Foerster LLP. Mr. Singh is a member of the State Bar of California.
Ralph Snodgrass, Ph.D.
President, Chief Scientific Officer, Director
Dr. Snodgrass founded VistaGen in 1998. He has over 18 years of experience in senior biotechnology management,
including as Chief Scientific Officer of Progenitor, Inc. He has more than 10 years of research experience as a professor
at the Lineberger Comprehensive Cancer Center, University North Carolina Chapel Hill School of Medicine, and as
a member of the Institute for Immunology, Basel, Switzerland. Dr. Snodgrass is a past Board Member of the Emerging
Company Section of the Biotechnology Industry Organization (BIO), and is a published and recognized pioneering expert
in stem cell biology with more than 20 years' experience in the uses of stem cells as biological tools for drug discovery
and development.
Gordon Keller, Ph.D.
Chairman, Scientific Advisory Board
Dr. Keller, recently named a "Top 25 Transformational Canadian" for his stem cell research, was appointed Director of
the McEwen Centre for Regenerative Medicine of the University Health Network in Toronto in 2007. He has published
more than 100 papers and is named on five patents. Dr. Keller is a former president of the International Society for Stem
Cell Research (ISSCR), the primary international organization of stem cell researchers, representing 3,800 scientists,
ethicists and clinicians worldwide. He is the Canada Research Chair in Embryonic Stem Cell Biology, a Professor at the
University of Toronto and a Senior Scientist in the Division of Stem Cell and Developmental Biology at the Ontario Cancer
Institute. Dr. Keller was a Professor in the Department of Gene and Cell Medicine at the Mt. Sinai School of Medicine in
New York where he was described by New York Magazine as one of "six doctors New York can't lose."
VSTA Key Investment Highlights
Proprietary Stem Cell Technology Addressing Major Safety Challenges in Drug Development
Drug Rescue Platform Designed to Recapture Prior R&D Investment in New Drug Candidates
New Drug Candidate for Neuropathic Pain in NIH-funded Phase Ib Clinical Trials
Management Team with Decades of Relevant Experience
Stem Cell Technology Aimed at Saving Millions of Healthcare Dollars
VSTA- Thin and ready. Low float that is held buy 95% inside. Easy to move on volume.
VSTA-It is also estimated that about one-third of all potential new drugs candidates fail in preclinical or clinical trials due to safety concerns. VSTA picks these up after other companies invest millions of dollars and years of research.
VSTA-It is also estimated that about one-third of all potential new drugs candidates fail in preclinical or clinical trials due to safety concerns. VSTA picks these up after other companies invest millions of dollars and years of research.
VSTA Plays it smart, The U.S. is facing a drug discovery crisis. Over the past decade, the number of new drugs approved by the U.S. Food and Drug Administration (FDA) has plummeted by more than 50%, despite substantial increases in research and development funding by the pharmaceutical industry. It has been estimated that drug discovery, development and commercialization programs of major pharmaceutical companies have required an average investment of approximately $800 million to $1.7 billion and 12 to 15 years before a new drug candidate reaches the market.After spending millions of dollars to discover, optimize and validate the potential efficacy of a promising new drug candidate and advance it into late-stage preclinical development, a pharmaceutical company can see it fail to progress due to unexpected heart or liver toxicity. The pharmaceutical company then often discontinues the development program for the once promising drug candidate and it is simply “put on the shelf” despite positive data indicating its potential therapeutic and commercial benefits. As a result, the pharmaceutical company’s significant prior investment in preclinical development may be lost.
VSTA-In parallel with its drug rescue activities, VistaGen is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube(TM) platform.
VSTA- I think that there may be some action now, as I tried to look at the L2 and it wacked out, then looked at the chart and it showed a dip and a bounce, strange but maybe more volume.
VSTA’s Our Human Clinical Trials in a Test Tube™ platform is based upon a combination of proprietary and exclusively licensed stem cell technologies, including technologies developed over the last 20 years by renowned Canadian scientist, Dr. Gordon Keller, and Dr. Ralph Snodgrass, our founder, President and Chief Scientific Officer.
VSTA- Small tigtly help float helps low volume production on the PPS. I want to see a couple of thousand traded and watch it.
VSTA’s lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system. Neuropathic pain affects approximately 1.8 million people in the U.S. alone. To date, we have been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VSTA is involved with Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants (drug rescue variants) of promising drug candidates that have been discontinued during preclinical development (put on the shelf) due to heart or liver safety concerns.
VSTA- Picks up some projects that are in the later phases and save them lots of money and time.
VSTA- This is what investolike to see:
VSTA-Strategic collaborators are a cornerstone of VSTA's corporate development strategy. To date, they have strategically selected core collaborators that provide them with flexible access to world-class expertise in specific areas at a lower overall cost than developing and maintaining such expertise internally.
VSTA- With pending news being rumored, we could have an active second half of the day.
VSTA-Strategic collaborators are a cornerstone of VSTA's corporate development strategy. To date, they have strategically selected core collaborators that provide them with flexible access to world-class expertise in specific areas at a lower overall cost than developing and maintaining such expertise internally.
VSTA saves millions of dollars and many years off the entire process with the fact that they pick up these projects at the point that they do.
VSTA- Watch for significant volume here. New website might be a signal. This one is for real.
VSTA Watch this one, new website yesterday might just be a signal that something is brewing.
New website: www.vistagen.com